Drug Profile
Antithrombin III
Alternative Names: Antithrombin-III; Antithrombin-III-alpha; Athimbin; BI51.017; Kybernin; Kybernin P; NeuartLatest Information Update: 19 Nov 2021
Price :
$50
*
At a glance
- Originator CSL Behring
- Class Alpha globulins; Anticoagulants; Antithrombins; Antithrombotics
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Thrombosis
- Discontinued Septic shock; Toxaemia
Most Recent Events
- 16 Oct 2019 Gifu University Hospital and CSL Behring terminate a clinical trial in Thrombosis in Japan (UMIN000018074)
- 08 May 2019 Launched for Thrombosis in Japan (IV)
- 15 Jun 2015 Clinical trials in Thrombosis in Japan (IV) (UMIN000018074)